Torrent Pharma Q3 FY26 Revenue Rises 18% to ₹3,303 Crore
Torrent Pharma's Q3 FY26 consolidated revenue grew 18% to ₹3,303 crore. Year-to-date revenue increased 14% to ₹9,783 crore. Growth was driven by India (up 14% in Q3), the US (up 19% in Q3), and Brazil (up 27% in Q3). The results were presented to analysts on February 13, 2026.
The announcement of financial results and a presentation to analysts is a routine but important update for investors, impacting their short-term investment decisions.
The company reported significant year-on-year revenue growth across multiple segments, indicating strong business performance.
Torrent Pharmaceuticals Limited has announced its unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2025. The company presented this information to analysts on 13th February 2026.
For the third quarter of FY26, Torrent Pharma reported a consolidated revenue of ₹3,303 crore, marking an 18% increase compared to ₹2,809 crore in the same period last year. This growth was driven by strong performance across key markets. Revenue from India increased by 14% to ₹1,798 crore, while the United States saw a 19% rise to ₹321 crore. Germany reported an 8% growth to ₹304 crore, and Brazil experienced a significant 27% increase to ₹371 crore. The 'Others' segment also grew by 32% to ₹509 crore.
On a year-to-date basis for the nine months ended December 2025, the total consolidated revenue stood at ₹9,783 crore, a 14% increase from ₹8,557 crore in the corresponding period of the previous year. India contributed ₹5,430 crore (up 12%), the United States ₹967 crore (up 21%), Germany ₹916 crore (up 7%), Brazil ₹907 crore (up 21%), and 'Others' ₹1,563 crore (up 20%).
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.